Atkinson et al.,Absence de nécessité de prévention contre le Pneumocystis jirovecii chez les adultes vivant avec le VIH
Absence de nécessité de prévention contre le Pneumocystis jirovecii chez les adultes vivant avec le VIH sous traitement antirétroviral et ayant des cellules CD4 supérieures à 100 cellules/μl.  Journal of the International AIDS Society La pneumonie causée par le champignon Pneumocystis jirovecii (PcP) est l’une des infections les plus fréquentes chez les patient.e.s vivant avec […]
Atkinson et al., La terapia preventiva contro il Pneumocystis jirovecii non è necessaria negli adulti che vivono con HIV
La terapia preventiva contro il Pneumocystis jirovecii non è necessaria negli adulti che vivono con HIV sotto terapia antiretrovirale e che hanno un tasso di linfociti CD4+ > 100/μl.  Journal of the International AIDS Society La polmonite causata dal fungo Pneumocystis jirovecii (PcP) è una delle infezioni opportunistiche più frequenti nei pazienti che vivono con […]
Atkinson et al., Keine vorbeugenden Antibiotika bei Erwachsenen mit HIV unter ART
Keine vorbeugenden Antibiotika bei Erwachsenen mit HIV unter antiretroviraler Therapie bei einer CD4-Zellzahl über 100 Zellen/μl erforderlich.  Journal of the International AIDS Society Die Lungenentzündung, verursacht durch den Pilz Pneumocystis jirovecii (PcP), ist eine der häufigsten Komplikationen der HIV-Infektion. Sie tritt bei unbehandelten Patientinnen und Patienten mit schwerer Abwehrschwäche (tiefen CD4-Lymphozyten) auf. Diese Lungenentzündung muss […]
Bannister et al., Changes in BMI and clinical outcomes
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens.  AIDS Bannister et al. for the EuroSIDA study group aimed to assess changes in body mass index (BMI) distribution during the period 2010–2019 and to investigate whether changes in BMI during this time of contemporary antiretroviral therapy (ART) are associated […]
Riebensahm et al. Liver steatosis among people with HIV
Factors associated with liver steatosis in people living with HIV on contemporary antiretroviral therapy.  Open Forum Infectious Diseases Riebensahm et al. aimed to describe determinants of liver steatosis among people living with HIV (PLWH) who receive antiretroviral therapy (ART) in the Swiss HIV Cohort Study. Between November 2019 and August 2021, individuals without HBV or […]
Jakeman et al., Anticholinergic and sedative medications and neurocognitive performance in PWH
Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virus.  Open Forum Infectious Diseases Jakeman et al. for the NAMACO Study Group aimed to further evaluate the effect of anticholinergic (ACH) and sedative medications on neurocognitive functions in the Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) […]
Kusejko et al., Effet durable sur l’élimination de l’hépatite C
Effet durable sur l’élimination de l’hépatite C chez les HSH dans la SHCS à deux ans d’un programme de dépistage systématique de l’ARN de l’hépatite C.  Clinical Infectious Diseases En 2016, l’Organisation mondiale de la santé (OMS) a publié sa première stratégie globale pour l’élimination de l’hépatite C. Le plan d’action de l’OMS comprend notamment […]
Byonanebye et al., Incidence of hypertension in people with HIV treated with INSTIs
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.  HIV Medicine Byonanebye et al. on behalf of the RESPOND consortium aimed to compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitors (INSTI-) based regimens versus those […]
Kusejko et al., Effetto duraturo sull’eliminazione dell’epatite C
Effetto duraturo sull’eliminazione dell’epatite C negli uomini che hanno rapporti sessuali con altri uomini (MSM) nella SHCS, due anni dopo l’inizio del programma di depistaggio sistematico tramite RNA del virus dell’epatite C.  Clinical Infectious Diseases Nel 2016, l’Organizzazione Mondiale della Sanità (OMS) ha pubblicato la sua prima strategia globale per l’eliminazione dell’epatite C. Il piano […]
Kusejko et al., Nachhaltige Wirkung bei der Eliminierung von Hepatitis C
Nachhaltige Wirkung bei der Eliminierung von Hepatitis C bei MSM aus der SHCS dank erneutem Screening auf Hepatitis-C-RNA.  Clinical Infectious Diseases Im Jahr 2016 veröffentlichte die Weltgesundheitsorganisation (WHO) ihre erste globale Strategie zur Eliminierung von Hepatitis C. Der Aktionsplan der WHO beinhaltet insbesondere sogenannte Mikro-Eliminierungsprogramme für Gruppen von Personen, welche besonders stark von der Hepatitis […]